Disruptions in the microbiome are increasingly being linked to an associated risk for serious illnesses, opening up vast potential to create a new category of innovative microbiome-based live biotherapeutics to help people live better lives and advance current standards of care.

Today, Dr James Tursi, Chief Scientific Officer of Ferring Pharmaceuticals, discusses study results of Ferring’s Phase III Trial for their microbiome-based live therapeutic (RBX2660), used in the treatment of recurrent C Difficile, and how to harness the potential of the the fast-emerging world of microbiome-based therapeutics.

Key takeaways:

Why now is the right time to tackle the microbiome
Results and impact of Ferring's RBX2660 treatment
Next steps for the industry

About the speaker:

Dr James Tursi is Chief Scientific Officer, Ferring Pharmaceuticals, responsible for US Clinical Development, Pharmaceutical Development, Medical Affairs, Pharmacovigilance, Project Planning and Regulatory Affairs. Prior to joining Ferring, as EVP, R&D, Chief Medical Officer for Antares Pharmaceuticals, he created patent extension and portfolio opportunities, was the medical-clinical-PV lead for commercial and business development activities and designed the medical/clinical commercial strategies. Before joining Antares, James held positions of increasing responsibility at Aralez Pharmaceuticals, Auxilium Pharmaceuticals, GlaxoSmithKline, and Procter & Gamble Pharmaceuticals. His therapeutic expertise includes reproductive health, urology, endocrinology (including pediatric), gastroenterology, cardiology, vascular surgery, oncology and neurology.

For more information about PharmaTalk Radio, visit theconferenceforum.org.

Ferring on Creating a First-in-Class Microbiome-Based Therapeutic

Share

Embed